Pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases
- Authors: Djawad K.1
-
Affiliations:
- Hasanuddin University
- Issue: Vol 97, No 1 (2021)
- Pages: 46-53
- Section: CLINICAL CASE REPORTS
- URL: https://journals.rcsi.science/0042-4609/article/view/117550
- DOI: https://doi.org/10.25208/vdv1196
- ID: 117550
Cite item
Full Text
Abstract
Introduction. Morbus Hansen is the infectious disease which causes by bacilli intracellular Mycobacterium leprae which mainly affects the skin and peripheral nerves. The leprosy reaction is an episode an immunologically mediated episode of acute or subacute inflammation which affecting skin; nerve; mucous membrane. Type 2 reactions can be last for months and risk of developing dependence on steroids. Pentoxifylline (PTX) works to hampers the production TNFá in vitro and in vivo; are an alternative for ENL treatment.
Case Report. One case was reported in a male aged 28 years with complaints of recurring red bumps accompanied by fever and pain.
Discussion. On physical examination obtained erythema nodosum; with impaired sensibility in the left leg. The patient experienced improvement after being given therapy of neurodex/24 hours/oral; rifampicin 600 mg; ofloxacin 400 mg; minocycline 100 mg which given 3x for a week; and combination therapy to treat the Leprosy reaction given the combination of methylprednisolone 16mg (3-2-0) and Pentoxifylline 400 mg/8 hours/oral.
Conclusion. In the 21 day of treatment; the redness lump improved in the middle finger and left arm was gone. No new reddish bumps appeared and less tingling sensation.
Full Text
##article.viewOnOriginalSite##About the authors
Khairuddin Djawad
Hasanuddin University
Author for correspondence.
Email: duddin@ymail.com
ORCID iD: 0000-0002-4569-6385
Doctor, Indonesia Faculty of Medicine
Indonesia, Jl. Perintis Kemerdekaan Km.10; 90245References
- Rodrigues LC; Lockwood DNj. Leprosy now: epidemiology; progress; challenges; and research gaps. Lancet Infect Dis. 2011;11(6):464–470. doi: 10.1016/S1473-3099(11)70006-8
- World Health Organization; “Global leprosy update; 2015: time for action; accountability and inclusion.; Relev Epidemiol Hebd; 2015;2;91(35):405–420. English; French. doi: 10.1186/1750-9378-2-15.Voir
- Zaenglein AL; Graber EM. Fitzpatrick’s Dermatology in general medicine In: Goldsmith LA; Katz SI; Gilchrest BA; Paller AS; Leffell DJ; editors. 8th ed.; New York: McGraw-Hill; 2012.
- Kamath S; Vaccaro SA; Rea TH; Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol 2014;24;71(4):795–803. doi: 10.1016/j.jaad.2014.03.034
- Pulido-Pérez A; Suárez Fernández R. Leprosy reactions and their management. Piel. 2015;30(10). doi: 10.1016/j.piel.2015.04.015
- World Health Organization; Leprosy Reaction and its Management. 2013.
- de Carsalade GY; Achirafi A; Flageul B. Efficacité de la pentoxifylline dans le traitement de l'érythème noueux lépreux: résultats d'une étude ouverte [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. Acta Leprol. 2003;12(3):117–22 (In French)
- Scollard DM; Adams LB; Gillis TP; et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338–381.
- doi: 10.1128/CMR.19.2.338-381.2006
- Britton WJ; Lockwood DNJ. Leprosy. The Lancet. 2004;363(9416):1209–1219. doi: 10.1016/S0140-6736(04)15952-7
- Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119–125.
- doi: 10.1358/dnp.2009.22.2.1303818
- Negera E; Walker SL; Girma S; et al. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital; Ethiopia. PLoS Negl Trop Dis. 2017;13;11(10):e0006011.
- doi: 10.1371/journal.pntd.0006011
- Sanghi S. IAL Textbook of Leprosy. Med J Armed Forces India. 2010;66(3):284. doi: 10.1016/s0377-1237(10)80066-8
- Di Lernia V. Linear and whorled hypermelanosis. Pediatr Dermatol. 2007;24(3):205–210. doi: 10.1111/j.1525-1470.2007.00387.x
- Pratiwi FD; Agusni I; Staf D; et al. Kelainan Sistemik dan Laboratoris pada Pasien Kusta dengan Reaksi Tipe 2 (Erythema Nodosum Leprosum) (Systemic and Laboratory Abnormalities of Leprosy Patients with Type 2 Reaction (Erythema Nodosum Leprosum). 2013;2.
- Županić-Krmek; Sučić M; Bekić D. Anemia of chronic disease: illness or adaptive mechanism. Acta Clin Croat. 2014;53(3):348–354.
- Murray J; Barbara JA; Dunkley SA; et al. Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood. 1997;90(7):2772–2783.
- Amulic B; Cazalet C; Hayes GL; et al. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30(1):459–489.
- doi: 10.1146/annurev-immunol-020711-074942
- Banerjee PN; Filippi D; Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85(1):31–45.
- doi: 10.1016/j.eplepsyres.2009.03.003
- Mahajan VK. Slit-skin smear in leprosy: lest we forget it! Indian J Lepr. 2013;85(4):177–183. doi: 10.1029/92JA01839
- Ishii N; Mori S; Nagaoka Y; Suzuki K. Report of the Ninth meeting of the WHO Technical Advisory Group of Leprosy Control. Nihon Hansenbyo Gakkai Zasshi = Japanese Journal of Leprosy: Official Organ of the Japanese Leprosy Association. 2009;78(1);75–88. doi: 10.5025/hansen.78.75
- Nery JA Da Costa; Sales AM; Illarramendi X; et al. Contribution to diagnosis and management of reactional states: A practical approach. An. Bras. Dermatol. [online]. 2006; 81(4):367–375.
- doi: 10.1590/S0365-05962006000400010
- Cayrol C; Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021–9026. doi: 10.1073/pnas.0812690106
- Hobbenaghi R; Javanbakht J; Hosseini E; et al. Neuropathological and neuroprotective features of vitamin B12 on the dorsal spinal ganglion of rats after the experimental crush of sciatic nerve: an experimental study. Diagn Pathol. 2013;31(8):123. doi: 10.1186/1746-1596-8-123
- Lopatina T; Kalinina N; Karagyaur M; et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One. 2011;14;6(3):e17899. doi: 10.1371/journal.pone.0017899
Supplementary files
